Get the Stockscreener App
42.69
1.26%
-0.545
Ionis Pharmaceuticals Inc stock is traded at $42.69, with a volume of 1.86M.
It is down -1.26% in the last 24 hours and up +1.76% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$43.23
Open:
$43.68
24h Volume:
1.86M
Relative Volume:
1.03
Market Cap:
$6.80B
Revenue:
$705.14M
Net Income/Loss:
$-453.90M
P/E Ratio:
-14.04
EPS:
-3.04
Net Cash Flow:
$-551.29M
1W Performance:
-2.49%
1M Performance:
+1.76%
6M Performance:
+32.09%
1Y Performance:
-10.20%
1-Day Range:
$42.09
$43.72
1-Week Range:
$41.96
$44.99
52-Week Range:
$23.95
$50.43
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
42.69 | 6.92B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-01-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates - MSN
Ionis Pharmaceuticals Inc. Recovery Linked to Earnings Surprise2025 Market Sentiment & Weekly Watchlist for Consistent Profits - beatles.ru
Relief Rally in Ionis Pharmaceuticals Inc. Stock — Can It HoldWeekly Trading Summary & Expert-Curated Trade Recommendations - 선데이타임즈
Traders Watching For Reversal Pattern in Ionis Pharmaceuticals Inc.Trade Exit Summary & Risk Controlled Daily Trade Plans - sundaytimes.kr
What technical models suggest about Ionis Pharmaceuticals Inc.’s comebackJuly 2025 Analyst Calls & Safe Entry Point Alerts - Newser
How to use Fibonacci retracement on Ionis Pharmaceuticals Inc.July 2025 Final Week & Weekly Top Performers Watchlists - Newser
Vanguard Group Inc. Has $494.30 Million Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Ionis Pharmaceuticals Inc. stock chart pattern explained2025 Fundamental Recap & Risk Controlled Stock Alerts - Newser
Ionis Pharmaceuticals (NASDAQ:IONS) Given “Neutral” Rating at UBS Group - Defense World
Ionis Pharmaceuticals (IONS) – Investment Analysts’ Weekly Ratings Changes - Defense World
UBS Group Reaffirms “Neutral” Rating for Ionis Pharmaceuticals (NASDAQ:IONS) - Defense World
Ionis Pharmaceuticals shares rise 1.16% premarket after UBS raised its price target to $46. - AInvest
Institutional scanner results for Ionis Pharmaceuticals Inc.Recession Risk & Low Risk Entry Point Tips - Newser
Stocks Flashing Renewed Technical Strength: Ionis Pharmaceuticals - Investor's Business Daily
Ionis Pharmaceuticals Inc. Hits Price Floor — Bounce IncomingLow Capital High Return Stock Plans Reviewed - 선데이타임즈
UBS Reiterates Hold Rating for Ionis Pharmaceuticals with $46 Price Target - AInvest
Ionis Pharmaceuticals Gets Neutral Rating from UBS with $46 Price Target - AInvest
Ionis Pharmaceuticals (IONS) Analyst Rating Update by UBS | IONS Stock News - GuruFocus
Ionis Pharmaceuticals: UBS Raises PT to $46, Maintains Neutral Rating - AInvest
FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More - BioSpace
Trend analysis for Ionis Pharmaceuticals Inc. this weekSmart Trade Mapping with Entry Details - Newser
Will Ionis Pharmaceuticals' (IONS) Return to Profitability and Raised Guidance Shift Its Investment Narrative? - simplywall.st
Q3 EPS Estimate for Ionis Pharmaceuticals Reduced by Analyst - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Envestnet Asset Management Inc. - Defense World
Insider Transactions Reported | Ionis Pharmaceuticals(IONS)saw insider trading activity on 8/6/2025 - AInvest
Ionis Pharmaceuticals EVP Geary Richard S sells 10,000 shares at $42.86/share on August 5. - AInvest
S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas - insights.citeline.com
Ionis Pharmaceuticals Inc. stock momentum explainedWeekly Hot Stocks Based on Volume Flow - Newser
Ionis Pharma EVP Schneider sells $408,701 in stock By Investing.com - Investing.com South Africa
Hereditary Transthyretin Amyloidosis (hATTR) Pipeline - openPR.com
Ionis Pharmaceuticals Reports Strong Earnings and Growth - TipRanks
Ionis Pharmaceuticals (IONS): Morgan Stanley Upgrade and Future ProspectsNews and Statistics - IndexBox
Ionis Pharmaceuticals Inc. Stock Lags Behind Sector BenchmarksHigh Growth Low Risk Stock Selection Gets Analyst Nod - beatles.ru
Why Morgan Stanley Upgraded This Biotech Stock to a Buy - Yahoo Finance
Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency - MSN
What analysts say about Ionis Pharmaceuticals Inc. stockBreakout profit opportunities - Jammu Links News
How does Ionis Pharmaceuticals Inc. compare to its industry peersGet exclusive access to expert stock recommendations - Jammu Links News
What are Ionis Pharmaceuticals Inc. company’s key revenue driversFree Popular Stock Recommendations - Jammu Links News
What institutional investors are buying Ionis Pharmaceuticals Inc. stockCapitalize on market momentum for maximum gains - Jammu Links News
Ionis Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Is it the right time to buy Ionis Pharmaceuticals Inc. stockBuild wealth steadily with proven investment techniques - Jammu Links News
Why is Ionis Pharmaceuticals Inc. stock attracting strong analyst attentionAchieve breakthrough profits with expert advice - Jammu Links News
Is Ionis Pharmaceuticals Inc. a growth stock or a value stockMarket-crushing profits - Jammu Links News
Ionis raises 2025 revenue guidance to $850M with Tryngolza momentum and Donidalorsen launch on track - MSN
How volatile is Ionis Pharmaceuticals Inc. stock compared to the marketCapital growth strategies that work - Jammu Links News
What makes Ionis Pharmaceuticals Inc. stock price move sharplyBuild wealth with high-performing stocks - Jammu Links News
What are analysts’ price targets for Ionis Pharmaceuticals Inc. in the next 12 monthsBreakthrough financial growth - Jammu Links News
Ionis Pharmaceuticals (NASDAQ:IONS) Earns “Buy” Rating from HC Wainwright - Defense World
What is Ionis Pharmaceuticals Inc. company’s growth strategyUnprecedented profits - Jammu Links News
What catalysts could drive Ionis Pharmaceuticals Inc. stock higher in 2025Invest confidently with professional advice - Jammu Links News
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ionis Pharmaceuticals Inc Stock (IONS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BENNETT C FRANK | EVP, Chief Scientific Officer |
Aug 18 '25 |
Sale |
43.98 |
10,000 |
439,776 |
93,466 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):